Rusan Pharma plant still breaks GMP rules says UK MHRA

By Gareth Macdonald

- Last updated on GMT

iStock/Cucu Remus
iStock/Cucu Remus

Related tags Healthcare products regulatory

Quality systems at a plant run by Rusan Pharma still break GMP rules according to a MHRA statement of non-compliance published this week.

The statement​ details a number of deviations from good manufacturing practices (GMP) observed during an inspection of the facility in Gandhidham, Gujarat in January.

Criticism focuses on quality control systems used at the facility which – according to Medicines and Healthcare Products Regulatory Agency (MHRA)– are not sufficient to ensure that patient safety is protected​.

The UK watchdog also said systems designed to detect cross contamination “could not assure adequate assessment​.”  It also criticised Rusan’s packaging operations and its staff training programmes.

The firm did not respond to a request for comment.

Regulatory problems

Rusan has been criticised by regulators before for quality oversight.

In April 2011 the EDQM suspended​ CEPs for four products: naltrexone hydrochloride, buprenorphine, fentanyl, and buprenorphine hydrochloride following a manufacturing inspection.

A year later the MHRA issued the Gandhidham site with a letter of non-compliance. The firm has not supplied any products to the UK since November of that year.

According to Rusan’s website activities at the Gandhidham facility – which is 792km north of Mumbai in the Kandla Special Economic Zone – include the production of tablets, capsules and injectable drugs.

Also, according to Rusan the facility was designed as per US FDA guidelines and has approval from MCC - South Africa and MCAZ - Zimbabwe.

Related news

Related products

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Related suppliers

Follow us


View more